Glioblastoma Evidence

Glioblastoma is the most common primary CNS malignancy, and it is a highly aggressive tumor with poor overall prognosis. Diagnosis of glioma is based on IDH wildtype status and a combination of either histologic and/or molecular criteria. MGMT promoter methylation is associated with improved outcomes compared to unmethylated tumors. Management consists of maximal safe resection, chemoradiotherapy with temozolomide (TMZ), and adjuvant TZ with tumor treating fields when appropriate. Here, we discuss evidence base for management of GBM, including standard of care, options for elderly and frail patients, and importance of clinical trial enrollment.

This presentation is created purely for educational purposes and does NOT constitute medical advice. If there are any errors or questions/concerns, we welcome comments and discussion!

Join the Rad Onc Study Club to get access to mock oral board style case reviews!
   / @rad_onc_talks